← Back to home
Trust Score: 35%

Trust Score calculated by AI analyzing study rigor, sample size (n), and the scientific source impact factor.

9/29/2026

Simvastatin restores spatial memory in β‑amyloid‑injected mice by reducing HDAC2 and increasing BDNF

Summary

“Simvastatin reversed β‑amyloid‑induced cognitive deficits in mice, normalizing HDAC2, histone H4 acetylation, and BDNF levels”

AC
Adrian CastroEditorially reviewed

Adrian Castro created Biohacker Age to have a place to closely follow longevity and biological optimization research without relying on sensationalist headlines. Content is produced with AI assistance from scientific literature and is editorially reviewed before publishing.

About our methodology →

The Finding


Cai and colleagues at the Institute of Mental Health and Drug Discovery reported that simvastatin restored spatial memory in male C57BL/6 mice injected intracerebroventricularly with Aβ₁₋₄₂, using a controlled experimental design with an unspecified number of subjects.

How They Got There


The study employed an Aβ₁₋₄₂‑induced Alzheimer’s disease mouse model. Mice received daily simvastatin or vehicle after surgery. Cognitive function was measured with the Morris Water Maze, Y‑maze, and Novel Object Recognition tests. Molecular analyses included Western blotting for HDAC2 and BDNF, chromatin immunoprecipitation for histone H4 acetylation at Bdnf promoters, and electrophysiological recordings of long‑term potentiation. Neurogenesis was assessed histologically. A viral vector overexpressing HDAC2 and a TrkB‑Fc fusion protein were used to probe causality.

The Mechanism: What Happens Biologically


Simvastatin lowered HDAC2 levels in the dorsal hippocampus, which lifted repression of histone H4 acetylation (Ac‑H4K5) at Bdnf promoter regions. The epigenetic shift permitted increased transcription of BDNF, raising its protein concentration. Elevated BDNF enhanced synaptic plasticity, evident as improved long‑term potentiation, and promoted the generation of new neurons in the hippocampal dentate gyrus.

Study Limitations



  • Absence of a reported sample size hampers assessment of statistical power.

  • Findings derive exclusively from an acute mouse model; translational relevance to human Alzheimer’s disease remains uncertain.

  • Behavioral testing spanned only a few weeks post‑treatment, leaving long‑term durability of the effects unknown.

Practical Application


It is too early to apply this protocol to personal performance optimization. Human trials confirming dose‑response, safety, and cognitive benefit are required before any actionable recommendation can be made.



Disclaimer: This article is for informational and educational purposes only. The information presented does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before modifying your diet, supplementation, or exercise routines. The scientific studies cited reflect the state of knowledge at their publication date and may be subject to revision.

Legal Notice

Medical Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or supplementation.

Science in your inbox

The most relevant studies of the week, curated and analyzed.

No spam. Unsubscribe anytime.